Deals In Depth: September 2010
Executive Summary
With the largest up-front ever for a Phase II candidate, Abbott's license to Reata's CKD compound bardoloxone topped the September alliance list. J&J expanded into vaccines through the Crucell buy, and Genzyme divested its esoteric testing division Genzyme Genetics to LabCorp for $925 million. Biopharma FOPOs and early-stage VC rounds were the most lucrative financing vehicles in September, with each type bringing in around $180 million of the $691 million total. The majority of device fundraising came from MicroPort Scientific's IPO.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.